Dorthe Kot Engelund

Title: Innovations by Dorthe Kot Engelund

Introduction

Dorthe Kot Engelund is a prominent inventor based in Holte, Denmark. She has made significant contributions to the field of pharmaceuticals, particularly in the development of innovative compositions and therapies. With a total of 8 patents to her name, Engelund's work has had a substantial impact on medical science.

Latest Patents

Engelund's latest patents include groundbreaking inventions such as "GLP-1 compositions and uses thereof." This invention relates to pharmaceutical compositions of the GLP-1 peptide semaglutide, which comprises no more than 0.1% (w/w) phenol and above 6.4 mg/ml sodium chloride. The patent also covers their preparation, kits comprising such compositions, and various uses thereof. Another notable patent is for "Stable multi-dose compositions comprising an antibody and a preservative." This invention focuses on stable, multi-dose liquid compositions containing proteins, particularly stable antibodies, and their therapeutic applications, especially for subcutaneous delivery.

Career Highlights

Dorthe Kot Engelund is currently associated with Novo Nordisk A/S, a leading global healthcare company. Her work at Novo Nordisk has allowed her to explore innovative solutions in diabetes care and other therapeutic areas. Engelund's expertise in pharmaceutical compositions has positioned her as a key player in the industry.

Collaborations

Engelund has collaborated with notable colleagues, including Claude Bonde and Tina Bjeldskov Pedersen. These collaborations have fostered a creative environment that encourages the development of new ideas and solutions in the pharmaceutical field.

Conclusion

Dorthe Kot Engelund's contributions to pharmaceutical innovations are noteworthy, with her patents reflecting her commitment to advancing medical science. Her work continues to influence the development of effective therapies, showcasing her role as a leading inventor in the industry.